{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:01:10Z","timestamp":1781478070401,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clbc.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T11:54:18Z","timestamp":1700913258000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brain Metastases in the Setting of Stable Versus Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Isabella","family":"Kojundzic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A. Carmona","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Moravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2023.11.008_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.clbc.2023.11.008_bib0002","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.clbc.2023.11.008_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.780379","article-title":"Clinical trial eligibility criteria and recently approved cancer therapies for patients with brain metastases","volume":"11","author":"Tan","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2023.11.008_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","article-title":"Breast cancer brain metastases: biology and new clinical perspectives","volume":"18","author":"Witzel","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2023.11.008_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2017.02.006","article-title":"Systematic analysis of early phase clinical studies for patients with breast cancer: inclusion of patients with brain metastasis","volume":"55","author":"Costa","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.clbc.2023.11.008_bib0006","first-page":"e1274","article-title":"HER2-positive breast cancer brain metastasis: a new and exciting landscape","volume":"5","author":"Zimmer","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"10.1016\/j.clbc.2023.11.008_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs Placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clbc.2023.11.008_bib0008","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2023.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clbc.2023.11.008_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2023.11.008_bib0011","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.clbc.2023.11.008_bib0012","doi-asserted-by":"crossref","first-page":"e1951","DOI":"10.1002\/onco.13965","article-title":"Treatment patterns and outcomes of women with symptomatic and asymptomatic breast cancer brain metastases: a single-center retrospective study","volume":"26","author":"Gao","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2023.11.008_bib0014","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4155\/cli.11.91","article-title":"Inclusion of patients with brain metastases in clinical trials","volume":"1","author":"Abrey","year":"2011","journal-title":"Clin Investig (Lond)"},{"key":"10.1016\/j.clbc.2023.11.008_bib0015","unstructured":"US Food and Drug Administration. Cancer clinical trial eligibility criteria: brain metastases guidance for industry. FDA Website (2019)."},{"issue":"7","key":"10.1016\/j.clbc.2023.11.008_bib0016","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaoncol.2021.1359","article-title":"Central nervous system-specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung cancer, and melanoma","volume":"7","author":"Corbett","year":"2021","journal-title":"JAMA Oncol"},{"issue":"33","key":"10.1016\/j.clbc.2023.11.008_bib0017","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2023.11.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25424","article-title":"Analysis of rates of brain metastases and association with breast cancer subtypes in Ontario, Canada","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.clbc.2023.11.008_bib0019","first-page":"265","article-title":"Brain-metastatic triple-negative breast cancer cells regain growth ability by altering gene expression patterns","volume":"10","author":"Choi","year":"2013","journal-title":"Cancer Genomics Proteomics"},{"issue":"16","key":"10.1016\/j.clbc.2023.11.008_bib0020","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.3390\/cancers13164137","article-title":"Molecular mechanisms associated with brain metastases in HER2-positive and triple negative breast cancers","volume":"13","author":"Bryan","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.clbc.2023.11.008_bib0021","doi-asserted-by":"crossref","first-page":"163","DOI":"10.21037\/atm.2018.04.35","article-title":"Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies","volume":"6","author":"Brosnan","year":"2018","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.clbc.2023.11.008_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0475","article-title":"Association of brain metastases with survival in patients with limited or stable extracranial disease: a systematic review and meta-analysis","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"MAY","key":"10.1016\/j.clbc.2023.11.008_bib0023","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fonc.2019.00377","article-title":"Linac-based radiosurgery for patients with brain oligometastases from a breast primary, in the trastuzumab era-impact of tumor phenotype and prescribed SRS dose","volume":"9","author":"Armstrong","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2023.11.008_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-021-00235-7","article-title":"Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases","volume":"7","author":"Alhalabi","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2023.11.008_bib0025","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.bjc.6604941","article-title":"Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients","volume":"100","author":"Park","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2023.11.008_bib0026","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41416-023-02153-w","article-title":"Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases","volume":"128","author":"Bottosso","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2023.11.008_bib0027","first-page":"JCO2200520","article-title":"Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5S","key":"10.1016\/j.clbc.2023.11.008_bib0028","doi-asserted-by":"crossref","first-page":"605","DOI":"10.6004\/jnccn.2018.0043","article-title":"NCCN Guidelines updates: breast cancer","volume":"16","author":"Giordano","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clbc.2023.11.008_bib0029","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2023.11.008_bib0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clbc.2022.07.004","article-title":"Exclusion of patients with brain metastases in published phase III clinical trials for advanced breast cancer","volume":"22","author":"Sharma","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"33","key":"10.1016\/j.clbc.2023.11.008_bib0031","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923003038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923003038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:59Z","timestamp":1761513959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923003038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1526820923003038"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.11.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain Metastases in the Setting of Stable Versus Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}